Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction

Submission date

Recruitment status

25/07/2006 No longer recruiting

Registration date 14/08/2006

Overall study status

Completed

Last Edited 26/06/2020

Condition category
Circulatory System

Prospectively registered

Protocol added

? SAP not yet added

Results added

? Raw data not yet added

✓ Study completed

Plain English Summary

Not provided at time of registration and not expected to be available in the future

Contact information

Type(s)

Scientific

Contact name

Prof Karl Swedberg

Contact details

Göteborg University
Heart and Lung Institute
Department of Medicine
Sahlgrenska
University Hospital/Östra
Göteborg
Sweden
S 416 85

Additional identifiers

EudraCT/CTIS number 2006-000708-18

IRAS number

ClinicalTrials.gov number

Protocol/serial number

CL3-16257-063

Study information

Scientific Title

Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction: a three-year randomised double-blind placebo-controlled international multicentre study

Acronym

SHIFT

Study hypothesis

Demonstrate the superiority of ivabradine over placebo in the reduction of cardiovascular mortality and hospitalisations for worsening heart failure.

Ethics approval required

Old ethics approval format

Ethics approval(s)

First French Ethics Committee approval obtained on 06/06/2006 from the CCPPRB Ambroise Paré (dossier: 06 06 46).

Study design

Double-blind randomised placebo-controlled two parallel and balanced treatment arms study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Condition

Chronic heart failure

Interventions

S16257 tablets containing 2.5 or 5 or 7.5 mg of ivabradine versus matching placebos.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Ivabradine

Primary outcome measure

Composite endpoint made of cardiovascular mortality or hospitalisation for worsening heart failure

Secondary outcome measures

Composite and non-composite endpoints including all deaths and all hospitalisations, change in functional capacity and clinical symptoms of heart failure

Overall study start date

15/09/2006

Overall study end date

30/04/2010

Eligibility

Participant inclusion criteria

- 1. Male or female aged more than 18 years
- 2. Chronic heart failure
- 3. Left ventricular systolic dysfunction
- 4. Sinus rhythm

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

6500

Participant exclusion criteria

- 1. Unstable cardiovascular condition
- 2. Recent myocardial infarction or coronary revascularisation

3. Congenital heart disease
4. Severe valvular disease
5. Active myocarditis

Recruitment start date
15/09/2006

Recruitment end date
30/04/2010

LOCATIONS

Countries of recruitment
Argentina

Australia

Austria

Belgium

Brazil

Bulgaria

Canada

Chile

China

Denmark

Estonia

Finland

France

Germany

Greece

Hong Kong

Hungary

India

Czech Republic

Lithuania					
Malaysia					
Netherlands					
Norway					
Poland					
Portugal					
Romania					
Russian Federation					
Slovakia					
Slovenia					
Spain					
Sweden					
Turkey					
Ukraine					
United Kingdom					
Study participating centre					

Ireland

Korea, South

Italy

Latvia

Sponsor information

Göteborg University

Göteborg Sweden S 416 85

Organisation

Institut de Recherches Internationales Servier (France)

Sponsor details

50 rue Carnot Suresnes France 92284

Sponsor type

Industry

Website

http://www.servier.com/

ROR

https://ror.org/034e7c066

Funder(s)

Funder type

Industry

Funder Name

Institut de Recherches Internationales Servier (France)

Results and Publications

Publication and dissemination plan

Publication plan:

Summary results are published on https://clinicaltrials.servier.com.

For interventional Phase III studies ending after the 1st January 2014, the results are/will be published in scientific literature.

Intention to publish date

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from https://clinicaltrials.servier.com if a Marketing Authorisation has been granted after 1st January 2014.

IPD sharing plan summary

Available on request

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

- ·					
Basic results				No	No
Protocol article	protocol	01/01/2010		Yes	No
Results article	results	11/09/2010		Yes	No
Results article	results	11/09/2010		Yes	No
Results article	results	29/05/2012		Yes	No
Results article	results	19/11/2013		Yes	No
Results article	results	12/02/2016		Yes	No
Results article	results	24/03/2017		Yes	No
Results article	results	01/07/2020	26/06/2020	Yes	No